Results 61 to 70 of about 10,952 (242)

Ethical and legal issues in psychedelic harm reduction and integration therapy

Harm Reduction Journal, 2021
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits.
Brian Pilecki, Jason B. Luoma, Geoff J. Bathje, Joseph Rhea, Vilmarie Fraguada Narloch   +4 more
doaj   +1 more source

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Frontiers in Psychology, 2021
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context.
Ingmar Gorman, Ingmar Gorman, Ingmar Gorman, Ingmar Gorman, Elizabeth M. Nielson, Elizabeth M. Nielson, Elizabeth M. Nielson, Aja Molinar, Ksenia Cassidy, Ksenia Cassidy, Jonathan Sabbagh, Jonathan Sabbagh   +11 more
doaj   +1 more source

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold ...
Stefano Damiani, Marika Orlandi, Umberto Provenzani, Elisa Bortolin, Margherita Rovida, Riccardo Stefanelli, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Ricardo E. Carrion, Rolando I. Castillo‐Passi, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Barbara A. Cornblatt, Covadonga M. Diaz‐Caneja, Lauren M. Ellman, Abigayle Fogarty, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung‐Wan Kim, Nikolaos Koutsouleris, Zsuliet Kristof, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay A. Mittal, Josh Nguyen, Merete Nordentoft, Godfrey D. Pearlson, Nora Penzel, Jesus Perez, Diana O. Perkins, Albert R. Powers III, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Cassandra Wannan, Jijun Wang, Heather Wastler, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Cheryl M. Corcoran, Tina Kapur, Ofer Pasternak, Carrie E. Bearden, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Barnaby Nelson, Martha E. Shenton, Scott W. Woods, Paolo Fusar‐Poli   +73 more
wiley   +1 more source

Well-being as a primary endpoint in clinical trials: a call for consensus

npj Mental Health Research
Psychiatric trials typically define success as symptom reduction, yet patients prioritize meaning, vitality, and functioning. This imbalance undervalues experiential benefits, distorting clinical, policy, and FDA decisions.
Elliot Marseille, Hannes Kettner, Tyrone J. Sgambati, James G. Kahn, Stefano Bertozzi, Will Lucas, Robin Carhart Harris, Dacher Keltner, Charles Raison   +8 more
doaj   +1 more source

Psychedelics and neonihilism: connectedness in a meaningless world

Frontiers in Psychology, 2023
The resurgence of psychedelic research explicitly targets treating mental health conditions largely through psychedelics-assisted psychotherapy. Current theories about mechanisms of change in psychedelics-assisted psychotherapy focus on mystical ...
Patric Plesa, Rotem Petranker
doaj   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Regulatory Challenges of Integrating Psychedelics into Mental Health Sector

Psychoactives
Psychedelic substances have recently emerged as a promising method for treating mental health conditions, despite a history of stigmatization and restriction in use.
Kerem Kemal Soylemez, Emma Marie de Boo, Joanne Lusher   +2 more
doaj   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis

Scientific Reports
Classic psychedelics and MDMA have a colorful history of recreational use, and both have recently been re-evaluated as tools for the treatment of psychiatric disorders.
Lukas A. Basedow, Tomislav Majić, Nicklas Jakob Hafiz, Engi A. E. Algharably, Reinhold Kreutz, Thomas G. Riemer   +5 more
doaj   +1 more source